South Africa Medical Device Classification Rules, Disputes and the GLF-MD-14A Matrix

1. Key takeaways

The classification of medical devices in South Africa is governed by Notice 1515 Regulation 11: Class A (low risk), Class B (low-moderate risk), Class C (moderate-high risk) and Class D (high risk), with risk directed at patients, users or public health. Where classification is not clear or falls between two classes, rule 11(4) requires the higher risk class to be assigned; in the event of a dispute, SAHPRA determines the classification (SAHPGL-MD-04). The classification outcome is consolidated in the GLF-MD-14A classification matrix form, which serves as the common baseline for subsequent filings and inspections.

Three operating rules follow from the framework: apply every applicable rule rather than selecting convenient ones; where in doubt, take the higher class as a matter of law, not prudence; and re-verify classification whenever design or intended use changes, because Regulation 11(5) requires classification to be considered individually according to the design and intended use of the device.

2. Legal basis

The table below lists the official sources relied upon.

3. Expert insights

Insight 1: Taking the higher class is a statutory rule, not a conservative strategy. Regulation 11(4) expressly provides that where classification is not clear and a device falls into one class or between two classes, the classification rules direct it into the higher risk class. Section 3.2 of SAHPGL-MD-04 likewise provides that where several rules apply, the higher classification governs. If a company chooses a lower class on its own initiative and SAHPRA disagrees, the consequence is not a simple correction but an error running through the entire review pathway — the dossier, the evidence plan and the submission route would all have been built for the wrong risk level, and the rework multiplies.

Insight 2: Accessories are classified separately, and combinations take the highest class. The guideline is explicit: accessories are classified separately, not automatically with the parent device; where devices are used in combination, the rules apply to each device individually; the overall classification of a device group, system or procedure pack takes the highest classification of any individual device; and the presence of a registered medicine in a procedure pack does not affect the classification. These three rules mean a single technical file may legitimately contain several classification conclusions, and the matrix form must set out each of them item by item rather than assigning one label to the whole kit.

Insight 3: Where intended use is unclear, SAHPRA will presume according to prevailing clinical practice. The guideline provides that where the intended use of a device or IVD is unclear, SAHPRA will require the manufacturer or Authorised Representative to clarify; where no clarification is provided within the prescribed period, or the intended use remains unclear, the Authority will assume an intended use consistent with that generally accepted by current clinical practice. This provision is heavily unfavourable to companies — waiving the clarification right hands the classification decision to the regulator’s presumption. Responding actively and promptly to any clarification request is always better than silence, and the intended use stated in the labelling should be drafted to leave no room for ambiguity.

Insight 4: Additional rules 13 to 16 are the hot zone for international divergence. The guideline specifically draws the attention of manufacturers and distributors to rules 13, 14, 15 and 16 (additional rules), because their international application may not be consistent. The practical estimate: products implicated by these rules should be confirmed with SAHPRA in writing before submission, and the confirmation archived in the regulatory file. A written confirmation converts a potentially disputed classification into a settled baseline, which protects both the current submission and future inspections.

Insight 5: Classification changes with design and intended use, and must be re-verified annually. Regulation 11(5) requires classification to be considered individually according to the design and intended use of the device. This implies classification is not a one-time exercise — design changes, revisions to the instructions for use, and newly added indications can all alter the class. Companies should make classification review a standing annual action, with design and use changes serving as immediate triggers, so that a shift to a higher class is caught before the next filing rather than during an inspection.

4. Practical recommendations

The following actions keep classification decisions defensible over time.

1. Apply all applicable rules clause by clause, never selectively: skipped rules are the leading cause of classification error.
2. Where in doubt, always take the higher class: this is a statutory rule and the safest practice at once.
3. Consolidate the outcome in GLF-MD-14A and archive it: the form is the common baseline for filings and inspections.
4. Clarify actively whenever intended use is unclear: never waive the clarification right.
5. Confirm before submitting for products engaging rules 13 to 16.
6. Make classification an annual review item: any design or intended use change triggers a re-check.

5. Verification checklist

Confirm every item below when a classification decision is made or revisited.

• □ All applicable rules have been assessed clause by clause (not selectively applied)
• □ Unclear or borderline cases have taken the higher class per Regulation 11(4)
• □ Accessories have been classified separately, and combinations, systems and procedure packs take the highest class
• □ The classification matrix form GLF-MD-14A has been completed and archived
• □ The intended use is clear and traceable from the instructions for use and labelling
• □ The applicability of rules 13 to 16 has been assessed and, where necessary, confirmed with SAHPRA
• □ An annual classification review mechanism has been established
• □ Design and intended use changes are incorporated as triggers for classification review

Regulatory information verified as of 29 October 2026. The regulations, guidance and effective dates described in this article are limited to the official sources listed in the legal basis section above, as published on that date. Where official documents are subsequently updated, the latest published version prevails.

• South Africa local resources: GRZAN assists manufacturers from the Chinese mainland and overseas with SAHPRA medical device Establishment Licence (MDEL) applications and product registration preparation, including Authorised Representative (AR) scheme design, ISO 13485 certification pathway planning and CAB selection, GMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and adverse event reporting mechanisms.
• Service capabilities: product attribute determination and risk classification (Class A/B/C/D), establishment licence application and renewal, reliance pathway justification, technical documentation and Essential Principles conformity argumentation, labelling and instructions-for-use localisation (English), and post-market vigilance and annual compliance information submission support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.